SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001558370-19-009354
Filing Date
2019-10-29
Accepted
2019-10-29 20:30:10
Documents
64
Period of Report
2019-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q crvs-20190930x10q.htm 10-Q 2120594
2 EX-31.1 crvs-20190930ex311d49b08.htm EX-31.1 13522
3 EX-31.2 crvs-20190930ex3122b6a8d.htm EX-31.2 13465
4 EX-32.1 crvs-20190930ex32132945a.htm EX-32.1 13629
  Complete submission text file 0001558370-19-009354.txt   6517453

Data Files

Seq Description Document Type Size
5 EX-101.INS crvs-20190930.xml EX-101.INS 1349904
6 EX-101.SCH crvs-20190930.xsd EX-101.SCH 38429
7 EX-101.CAL crvs-20190930_cal.xml EX-101.CAL 53361
8 EX-101.DEF crvs-20190930_def.xml EX-101.DEF 113865
9 EX-101.LAB crvs-20190930_lab.xml EX-101.LAB 376317
10 EX-101.PRE crvs-20190930_pre.xml EX-101.PRE 265191
Mailing Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010
Business Address 863 MITTEN ROAD SUITE 102 BURLINGAME CA 94010 (650) 900-4520
Corvus Pharmaceuticals, Inc. (Filer) CIK: 0001626971 (see all company filings)

IRS No.: 464670809 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-37719 | Film No.: 191177132
SIC: 2834 Pharmaceutical Preparations